The Current state of Chest pain triage
There are as many as 8 million visits to the ER per year due to chest pain.¹ However, determining whether or not the cause of chest pain is due to Coronary Artery Disease or Acute Coronary Syndrome is a complex process for physicians.² Many patients will undergo multiple layers of diagnostic testing to minimize the risk of a missed cardiac event, which can be time consuming and expensive.
Challenges with Chest Pain Triage
Length of stay
Patients that go into the hospital for chest pain may be kept for an 8-23 hour stay.³ Long hospital stays are currently needed to rule out the possibility of a severe adverse cardiac event.
Wide Range of Testing
There are many diagnostic tests that patients may go through to find the cause of their chest pain. These include various types of stress tests that can involve pharmaceutical or exercise-based stress.
The many diagnostic tests plus long hospital stays make the triage process for chest pain very expensive.⁴ This cost is felt by both hospitals and patients.
Risks of Chest Pain Diagnosis
Misdiagnosing patients with chest pain may include inadvertent or premature discharge from the hospital. The risk of undertreating a patient with chest pain is a possible major adverse cardiac event (MACE). Many of the patients coming into the hospital for chest pain will not have a MACE.⁵ Despite this, patients are kept in the hospital under observation to minimize the possibility of under treating someone who needs further treatment.
Over treatment of patients with chest pain may include unnecessary invasive diagnostic testing or procedures. Since many individuals entering the ER for chest pain will ultimately not experience any major adverse cardiac events, it is important to provide serious medical treatment only to those who need it. There is a high risk of over treating because it is difficult to rapidly rule out the patients who are not in need of invasive procedures like cardiac catheterization.
Our MCG Solutions
CardioFlux Magnetocardiograph (MCG) is a FDA Cleared, non-invasive biomagnetic imaging system that requires no exercise or patient exposure to radiation. Leveraging over forty years of clinical investigation, CardioFlux MCG is intended for use as a tool to measure and display the magnetic signals produced by your heart.
Faraday Analytical Cloud™
CardioFlux MCG is powered by Faraday Analytical Cloud, the software that generates images of the patient’s magnetic field. Physicians can order scans and have the results within minutes through integrating Faraday with a hospital’s clinical and administrative systems.
Reinhardt, Samuel W., Chien-Jung Lin, Eric Novak, and David L. Brown. “Noninvasive cardiac testing vs clinical evaluation alone in acute chest pain: a secondary analysis of the ROMICAT-II randomized clinical trial.” JAMA internal medicine 178, no. 2 (2018): 212-219.
Frisoli, Tiberio M., Richard Nowak, Kaleigh L. Evans, Michael Harrison, Maath Alani, Saira Varghese, Mehnaz Rahman et al. “Henry Ford HEART score randomized trial: rapid discharge of patients evaluated for possible myocardial infarction.” Circulation: Cardiovascular Quality and Outcomes 10, no. 10 (2017): e003617.